Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | 343.96%7.07M | 676.80%9.07M | -50.16%3.6M | -12.44%20.35M | 53.35%14.85M | -2.9M | 1.17M | 7.23M | -25.53%23.25M | 16.11%9.69M |
| Net profit before non-cash adjustment | 79.83%8.15M | 12.72%6.68M | 318.07%8.1M | 10.62%20.82M | 93.78%8.43M | --4.53M | --5.92M | --1.94M | -26.74%18.82M | -24.41%4.35M |
| Total adjustment of non-cash items | -11.93%517K | 56.33%494K | -84.48%700K | -71.37%1.36M | -359.98%-4.05M | --587K | --316K | --4.51M | -27.59%4.77M | -42.91%1.56M |
| -Depreciation and amortization | 11.89%1.17M | 13.90%1.18M | 16.65%1.19M | -14.64%4.48M | 18.30%1.38M | --1.04M | --1.04M | --1.02M | -24.01%5.25M | -23.30%1.16M |
| -Reversal of impairment losses recognized in profit and loss | --0 | ---- | ---- | -90.61%13.05K | -91.82%11.05K | --0 | ---- | ---- | 306.43%139K | 300.49%135K |
| -Disposal profit | --0 | --0 | --0 | 32.20%-80K | --2K | --0 | ---82K | --0 | -10.63%-118K | --0 |
| -Net exchange gains and losses | -224.39%-357K | -206.98%-184K | 200.00%59K | -34.62%-445.59K | -362.61%-845.59K | --287K | --172K | ---59K | 22.82%-331K | -73.83%322K |
| -Other non-cash items | 60.57%-293K | 38.18%-502K | -115.51%-550K | -1,429.63%-2.6M | -7,075.59%-4.59M | ---743K | ---812K | --3.55M | -160.51%-170K | -231.31%-64K |
| Changes in working capital | 80.03%-1.6M | 137.55%1.9M | -761.66%-5.19M | -438.47%-1.83M | 177.16%10.47M | ---8.01M | ---5.07M | --785K | 67.84%-340K | 2,755.89%3.78M |
| -Change in receivables | 37.92%-5.27M | 32.33%-4.07M | 5.90%1.96M | -329.60%-4.31M | 674.76%8.36M | ---8.5M | ---6.02M | --1.85M | 398.99%1.88M | -52.59%1.08M |
| -Change in inventory | 68.38%-833K | 89.41%-216K | -1,011.90%-2.3M | -786.80%-6.38M | -1,483.84%-1.96M | ---2.63M | ---2.04M | --252K | 37.58%-720K | 84.24%-124K |
| -Change in payables | 44.69%4.51M | 107.26%6.19M | -269.25%-4.85M | 692.35%8.86M | 44.31%4.07M | --3.12M | --2.99M | ---1.31M | -306.73%-1.5M | 272.99%2.82M |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | ||||||||||
| Interest received (cash flow from operating activities) | ||||||||||
| Tax refund paid | -65.46%-1.93M | 3.20%-1.45M | -55.04%-2.23M | 16.42%-5.07M | 23.86%-971.48K | -1.16M | -1.5M | -1.44M | -18.08%-6.07M | 36.46%-1.28M |
| Other operating cash inflow (outflow) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating cash flow | 226.58%5.14M | 2,402.72%7.62M | -76.29%1.37M | -11.04%15.28M | 65.07%13.88M | ---4.06M | ---331K | --5.79M | -34.13%17.18M | 32.78%8.41M |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | -1,358.35%-19.4M | -1,259.09%-25.05M | --0 | -41.13%-26.86M | -11,442.51%-22.74M | ---1.33M | ---1.84M | ---953K | -471.76%-19.04M | 81.01%-197K |
| Net investment product transactions | 149.70%20.27M | -40.97%43.26M | 88.55%-7.8M | -1,130.38%-50.58M | -265.26%-14.94M | ---40.8M | --73.29M | ---68.14M | -23,557.71%-4.11M | -85,590.34%-4.09M |
| Advance cash and loans provided to other parties | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Interest received (cash flow from investment activities) | -55.31%345K | -33.76%563K | 4.72%621K | 536.57%2.79M | 369.83%573.19K | --772K | --850K | --593K | 318.53%438K | 258.76%122K |
| Investing cash flow | 102.96%1.22M | -74.03%18.78M | 89.52%-7.18M | -228.76%-74.66M | -790.86%-37.1M | ---41.35M | --72.3M | ---68.5M | -584.73%-22.71M | -313.23%-4.17M |
| Financing cash flow | ||||||||||
| Net issuance payments of debt | -4.71%-400K | -4.49%-396K | -4.81%-392K | -4.05%-1.52M | -4.68%-387.31K | ---382K | ---379K | ---374K | 58.43%-1.46M | -2.81%-370K |
| Net common stock issuance | --0 | --0 | --0 | --71.03M | --0 | --0 | --0 | --71.03M | --0 | --0 |
| Increase or decrease of lease financing | 3.56%-434K | 2.95%-428K | 3.86%-423K | 11.10%-1.75M | 12.80%-421.19K | ---450K | ---441K | ---440K | -3.69%-1.97M | 0.63%-483K |
| Issuance fees | --0 | --0 | --0 | ---5.34M | --0 | --0 | --0 | ---5.34M | --0 | --0 |
| Interest paid (cash flow from financing activities) | -79.31%-52K | -60.53%-61K | -47.92%-71K | 27.08%-195.44K | -38.68%-80.44K | ---29K | ---38K | ---48K | 30.50%-268K | 29.91%-58K |
| Financing cash flow | -2.90%-886K | -3.15%-885K | -101.37%-886K | 1,925.02%67.56M | 588.26%4.45M | ---861K | ---858K | --64.83M | 36.23%-3.7M | 1.91%-911K |
| Net cash flow | ||||||||||
| Beginning cash position | -46.55%53.41M | -3.25%27.87M | 29.66%34.57M | -25.45%26.66M | 128.66%53.27M | --99.91M | --28.81M | --26.66M | 97.49%35.76M | -26.76%23.3M |
| Current changes in cash | 111.83%5.48M | -64.12%25.52M | -414.91%-6.7M | 188.65%8.19M | -663.34%-18.78M | ---46.27M | --71.11M | --2.13M | -154.47%-9.23M | -24.19%3.33M |
| Effect of exchange rate changes | 81.57%-68K | 311.11%19K | -104.76%-1K | -309.33%-278.41K | 138.15%78.59K | ---369K | ---9K | --21K | -80.99%133K | 107.46%33K |
| End cash Position | 10.42%58.81M | -46.55%53.41M | -3.25%27.87M | 29.66%34.57M | 29.66%34.57M | --53.27M | --99.91M | --28.81M | -25.45%26.66M | -25.45%26.66M |
| Free cash flow | -164.51%-14.26M | -673.11%-17.43M | -71.63%1.37M | -489.95%-11.66M | -207.87%-8.86M | ---5.39M | ---2.25M | --4.84M | -108.76%-1.98M | 55.13%8.21M |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.